Neuromyelitis Optica Spectrum Disorder

Dean M. Wingerchuk; Claudia F. Lucchinetti

doi:10.1056/NEJMra1904655

Neuromyelitis Optica Spectrum Disorder

Dean M. Wingerchuk, Claudia F. Lucchinetti

Research output: Contribution to journal › Review article › peer-review

Abstract

The canonical clinical features of neuromyelitis optica have been supplemented by other characteristic syndromes and the finding of pathogenic AQP4-IgG autoantibodies. The expanded disease spectrum, NMOSD, is treated with drugs that target the steps in pathogenesis. Promising approaches to predicting and preventing relapses, enhancing recovery from relapse, and achieving immune tolerance are under investigation.

Original language	English (US)
Pages (from-to)	631-639
Number of pages	9
Journal	New England Journal of Medicine
Volume	387
Issue number	7
DOIs	https://doi.org/10.1056/NEJMra1904655
State	Published - Aug 18 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMra1904655

Cite this

@article{750db660fc744f669406312f56fd0695,

title = "Neuromyelitis Optica Spectrum Disorder",

abstract = "The canonical clinical features of neuromyelitis optica have been supplemented by other characteristic syndromes and the finding of pathogenic AQP4-IgG autoantibodies. The expanded disease spectrum, NMOSD, is treated with drugs that target the steps in pathogenesis. Promising approaches to predicting and preventing relapses, enhancing recovery from relapse, and achieving immune tolerance are under investigation.",

author = "Wingerchuk, {Dean M.} and Lucchinetti, {Claudia F.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Massachusetts Medical Society.",

year = "2022",

month = aug,

day = "18",

doi = "10.1056/NEJMra1904655",

language = "English (US)",

volume = "387",

pages = "631--639",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "7",

}

TY - JOUR

T1 - Neuromyelitis Optica Spectrum Disorder

AU - Wingerchuk, Dean M.

AU - Lucchinetti, Claudia F.

PY - 2022/8/18

Y1 - 2022/8/18

N2 - The canonical clinical features of neuromyelitis optica have been supplemented by other characteristic syndromes and the finding of pathogenic AQP4-IgG autoantibodies. The expanded disease spectrum, NMOSD, is treated with drugs that target the steps in pathogenesis. Promising approaches to predicting and preventing relapses, enhancing recovery from relapse, and achieving immune tolerance are under investigation.

AB - The canonical clinical features of neuromyelitis optica have been supplemented by other characteristic syndromes and the finding of pathogenic AQP4-IgG autoantibodies. The expanded disease spectrum, NMOSD, is treated with drugs that target the steps in pathogenesis. Promising approaches to predicting and preventing relapses, enhancing recovery from relapse, and achieving immune tolerance are under investigation.

UR - http://www.scopus.com/inward/record.url?scp=85137523016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137523016&partnerID=8YFLogxK

U2 - 10.1056/NEJMra1904655

DO - 10.1056/NEJMra1904655

M3 - Review article

C2 - 36070711

AN - SCOPUS:85137523016

SN - 0028-4793

VL - 387

SP - 631

EP - 639

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 7

ER -

Neuromyelitis Optica Spectrum Disorder

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this